Sanofi Consumer

Why is Sanofi Consumer Healthcare India Ltd falling/rising?

As of 05-Aug, Sanofi Consumer Healthcare India Ltd's stock is slightly rising at 4,535.50 after a trend reversal, but it has underperformed against the Sensex and shows declining investor interest. Despite these challenges, the company has strong management efficiency and positive financial results.

As of 05-Aug, Sanofi Consumer Healthcare India Ltd's stock price is experiencing a slight rise, currently at 4,535.50, reflecting an increase of 2.65 (0.06%). This uptick comes after a trend reversal, as the stock has gained after five consecutive days of decline. Despite this recent rise, the stock has been underperforming relative to the benchmark Sensex over various periods, including a 1-week decline of 3.59% compared to a 1.19% increase in the Sensex.<BR><BR>The stock is currently trading below its moving averages across multiple time frames, indicating a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume plummeting by 97.41% against the 5-day average, suggesting reduced interest from investors.<BR><BR>On a positive note, the company has demonstrated high management efficiency with a return on equity (ROE) of 67.74% and is net-debt free. Furthermore, it has reported positive results for the last four consecutive quarters, with net sales growing by 26.89% and achieving the highest profit after tax (PAT) of Rs 68.80 crore in the latest quarter. The high institutional holdings at 20.46% also indicate confidence from more sophisticated investors.<BR><BR>In summary, while the stock is currently rising slightly, it faces challenges such as recent underperformance relative to the market, declining investor participation, and trading below key moving averages.

Which are the latest news on Sanofi Consumer?

Are Sanofi Consumer Healthcare India Ltd latest results good or bad?

Sanofi Consumer Healthcare India Ltd's latest Q1 FY27 results show a net profit increase of 13.35% year-on-year and revenue growth of 6.70%. However, a decline in operating margin to 37.89% raises concerns about profitability amid rising costs.

Sanofi Consumer Healthcare India Ltd's latest results for Q1 FY27 show a mixed performance. On the positive side, the company reported a net profit of ₹68.80 crores, which is a 13.35% increase year-on-year and a 1.47% increase quarter-on-quarter. Revenue also grew by 6.70% year-on-year, reaching ₹235.70 crores, with a sequential growth of 2.84%.<BR><BR>However, there are concerns regarding the operating margin, which declined by 85 basis points to 37.89% compared to the previous quarter. This margin compression indicates challenges in maintaining profitability amidst rising costs and competitive pressures. <BR><BR>Overall, while the company has demonstrated strong profitability and growth in net profit and revenue, the decline in operating margin suggests that it is facing some headwinds. Investors should monitor these trends closely, especially the impact on margins moving forward.

Should I buy, sell or hold Sanofi Consumer Healthcare India Ltd?

When is the next results date for Sanofi Consumer Healthcare India Ltd?

The next results date for Sanofi Consumer Healthcare India Ltd is 28 July 2026.

The next results date for Sanofi Consumer Healthcare India Ltd is scheduled for 28 July 2026.

What does Sanofi Consumer do?

Sanofi Consumer Healthcare India Ltd, established on May 10, 2023, focuses on the Consumer Healthcare sector following its demerger from Sanofi India Limited. As of March 2026, it reported net sales of 229 Cr and a net profit of 68 Cr, with a market cap of INR 10,889 Cr.

Overview: <BR>Sanofi Consumer Healthcare India Ltd operates in the Pharmaceuticals & Biotechnology industry as a small-cap company focused on establishing a standalone Consumer Healthcare business.<BR><BR>History: <BR>Incorporated on May 10, 2023, Sanofi Consumer Healthcare India Ltd was formed as part of Sanofi's global strategy to create a distinct legal entity through the demerger of its Consumer Healthcare business from Sanofi India Limited. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 229 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 68 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 10,889 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 42.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.98 <BR>Return on Equity: 65.84% <BR>Price to Book: 28.36 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Sanofi Consumer?

As of 10th June, Sanofi Consumer Healthcare India Ltd has a market capitalization of 10,889.00 Cr, with recent net sales of 935.00 Cr and a net profit of 257.90 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Sanofi Consumer Healthcare India Ltd has a market capitalization of 10,889.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 935.00 Cr, while the sum of Net Profit for the same period is 257.90 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is December 2025, with Shareholder's Funds amounting to 384.00 Cr and Total Assets valued at 538.50 Cr.

Who are the peers of the Sanofi Consumer?

Sanofi Consumer's peers include Concord Biotech, Alivus Life, Marksans Pharma, Shilpa Medicare, Viyash Scientifi, P & G Health Ltd, Akums Drugs, and Strides Pharma. Most peers show Below Average growth and management risk, with Sanofi Consumer and P & G Health Ltd exhibiting Excellent capital structures and returns.

Peers: The peers of Sanofi Consumer are Concord Biotech, Alivus Life, Marksans Pharma, Shilpa Medicare, Viyash Scientifi, P & G Health Ltd, Akums Drugs, and Strides Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer and P & G Health Ltd, while Good management risk is found at Concord Biotech, Alivus Life, and Marksans Pharma. Below Average management risk is present at Shilpa Medicare, and Average management risk is noted at Viyash Scientifi and Akums Drugs. All peers exhibit Below Average growth, except for Sanofi Consumer and P & G Health Ltd, which maintain an Excellent capital structure alongside Concord Biotech, Alivus Life, and Marksans Pharma, while Akums Drugs has a Good capital structure, and Shilpa Medicare and Strides Pharma show Below Average capital structure.<BR><BR>Return Snapshot: Marksans Pharma has the highest 1-year return at -3.49%, while Concord Biotech has the lowest at -37.64%. Sanofi Consumer's 1-year return of -10.01% is better than Concord Biotech's but worse than Marksans Pharma's. Additionally, Shilpa Medicare is the only peer with a positive six-month return, while the rest have either negative or no data available.

Is Sanofi Consumer technically bullish or bearish?

As of December 2, 2025, Sanofi Consumer's technical trend has shifted to a bearish stance, driven by bearish MACD, Bollinger Bands, and moving averages, despite some divergence in longer-term perspectives indicated by Dow Theory.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on the weekly, and the OBV shows a mildly bearish trend. The Dow Theory indicates a mildly bearish stance on the weekly but is mildly bullish on the monthly, suggesting some divergence in longer-term perspectives. Overall, the bearish indicators dominate the current technical outlook for Sanofi Consumer.

How has been the historical performance of Sanofi Consumer?

Sanofi Consumer reported net sales of 724.50 crore and a profit after tax of 181.00 crore for the year ending December 2024, reflecting strong growth. Shareholder's funds increased to 273.00 crore, and cash and bank balances rose significantly to 326.90 crore.

Answer:<BR>The historical performance of Sanofi Consumer for the year ending December 2024 shows significant growth in various financial metrics compared to the previous year.<BR><BR>Breakdown:<BR>In December 2024, Sanofi Consumer reported net sales of 724.50 crore, with total operating income also at 724.50 crore. The total expenditure, excluding depreciation, was 453.90 crore, leading to an operating profit (PBDIT) of 283.60 crore. After accounting for interest and exceptional items, the profit before tax stood at 246.80 crore, resulting in a profit after tax of 181.00 crore. The earnings per share (EPS) was reported at 78.7, with a PAT margin of 24.98%. On the balance sheet, shareholder's funds increased to 273.00 crore from 207.60 crore in the previous year, while total liabilities rose to 425.10 crore from 343.50 crore. The total assets also increased to 425.10 crore, with cash and bank balances significantly rising to 326.90 crore from just 1.60 crore in December 2023. The cash flow from operating activities was 439.00 crore, contributing to a net cash inflow of 325.00 crore for the year.

Is Sanofi Consumer overvalued or undervalued?

As of April 19, 2025, Sanofi Consumer is considered very expensive and overvalued with a PE ratio of 57.64, significantly higher than its peers, and has underperformed the Sensex with a recent return of -6.91%.

As of 19 April 2025, the valuation grade for Sanofi Consumer has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a price-to-earnings (PE) ratio of 57.64, a price-to-book value of 42.77, and an EV to EBITDA ratio of 41.78. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Sanofi Consumer's PE ratio is notably higher than Sun Pharmaceutical Industries Ltd. at 35.25 and Cipla Ltd. at 22.99, both of which are considered attractive. Furthermore, the PEG ratio for Sanofi is 0.00, indicating no growth expectations, which contrasts sharply with the more reasonable valuations of its competitors. Recent stock performance shows that Sanofi has underperformed the Sensex over the past week, with a return of -6.91% compared to the Sensex's 1.35%. This reinforces the notion that the stock may be overvalued in the current market context.

Who are the top shareholders of the Sanofi Consumer?

The top shareholders of Sanofi Consumer include Opella Healthcare Participations B.V. with 60.4%, Life Insurance Corporation of India at 5.66%, and individual investors with 6.58%. Additionally, 18 mutual fund schemes hold 15.09%, while 102 foreign institutional investors have a total of 4.53%.

The top shareholders of Sanofi Consumer include Opella Healthcare Participations B.V., which holds the largest stake at 60.4%. Other significant shareholders are the Life Insurance Corporation of India, with a holding of 5.66%, and individual investors collectively owning 6.58%. Additionally, the company has 18 mutual fund schemes holding a combined 15.09% and 102 foreign institutional investors (FIIs) with a total holding of 4.53%. There are no pledged promoter holdings reported.

Has Sanofi Consumer declared dividend?

Yes, Sanofi Consumer Healthcare India Ltd has declared a 550% dividend, amounting to ₹55 per share, with an ex-date of April 17, 2025. However, total returns over the past year and longer periods have been stagnant, showing no price or dividend growth.

Sanofi Consumer Healthcare India Ltd has declared a 550% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 550%<BR>- Amount per share: 55<BR>- Ex-date: 17 Apr 25<BR><BR>Dividend Yield: 1.08%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.2%, the dividend return was 1.14%, resulting in a total return of 6.34%.<BR><BR>In the last 1 year, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the last 2 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 3 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the last 4 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 5 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Sanofi Consumer has declared a significant dividend, the total returns over longer periods indicate a lack of growth in price and dividends, suggesting a mixed performance in terms of shareholder returns.